Metraipolis › archive › dc_d3b6eee708ae

Mepolizumab for hypereosinophilic syndrome: effectiveness and safety from real-world evidence — Europe PMC PMID:41322417

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41322417
DOI
10.3389/fimmu.2025.1704077
License (as archived)
solo-consultazione
Archived
2026-11-08T13:29:08.810Z
SHA-256 of the archived text
7f5136e7061d199cb8cf3e040849a292d5fab40f9d998e0f26cc216234b56a3b
Stable URL of this page
https://metraipolis.com/documento/dc_d3b6eee708ae

How to cite

Mepolizumab for hypereosinophilic syndrome: effectiveness and safety from real-world evidence — Europe PMC PMID:41322417 — Europe PMC (en), https://europepmc.org/article/MED/41322417 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_d3b6eee708ae (Metraipolis archive dc_d3b6eee708ae, sha256 7f5136e7061d199cb8cf3e040849a292d5fab40f9d998e0f26cc216234b56a3b)
BibTeX
@misc{dcd3b6eee708ae,
  title = {Mepolizumab for hypereosinophilic syndrome: effectiveness and safety from real-world evidence — Europe PMC PMID:41322417},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41322417},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_d3b6eee708ae; sha256 7f5136e7061d199cb8cf3e040849a292d5fab40f9d998e0f26cc216234b56a3b},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41322417. Agents can read the archived copy with the MCP tool read_document.